Acknowledging and addressing real-world challenges to treating immune-related adverse events
Immune checkpoint inhibitors (ICIs) have revolutionized oncology treatment. However, their success is mitigated by the recognition that ICI-induced immune-related adverse events (irAEs) pose considerable challenges to patients and clinicians. These autoimmune toxicities are heterogeneous, unpredicta...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMJ Publishing Group
2024-07-01
|
| Col·lecció: | Journal for ImmunoTherapy of Cancer |
| Accés en línia: | https://jitc.bmj.com/content/12/7/e009540.full |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|